» Articles » PMID: 9142918

Role of Plasma Vasopressin As a Mediator of Nausea and Gastric Slow Wave Dysrhythmias in Motion Sickness

Overview
Journal Am J Physiol
Specialty Physiology
Date 1997 Apr 1
PMID 9142918
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The possible role of vasopressin in nausea and gastric dysrhythmias in motion sickness was tested by electrogastrography in 14 subjects during circular vection (60 degrees/s) and vasopressin infusion. Tachygastria was expressed as the signal percent >4.5 cycles/min. Vection evoked nausea scores of 2.6 +/- 0.2 (0 = none to 3 = severe) in 10 subjects with increases in tachygastric activity (15 +/- 2 to 45 +/- 3%) and plasma vasopressin (4.5 +/- 1.5 to 8.4 +/- 2.5 pg/ml) that were blocked by atropine but not indomethacin. Four asymptomatic subjects had no tachygastria or vasopressin release. Vasopressin at 0.2 U/min (plasma level = 322.1 +/- 10.3 pg/ml) evoked nausea (2.6 +/- 0.4) and increases in tachyarrhythmic activity (41 +/- 5%) that were blunted by atropine but not indomethacin. There were no differences in nausea or dysrhythmias with vasopressin infusion in subjects who noted nausea during vection versus those who did not. To conclude, vection evokes nausea, dysrhythmias, and vasopressin release in motion sickness-susceptible humans via cholinergic prostaglandin-independent pathways. Supraphysiological vasopressin infusions evoke nausea and dysrhythmias by similar pathways to equal degrees in motion sickness-susceptible and -resistant subjects. Thus central but not peripheral actions of vasopressin may contribute to nausea and slow wave disruption with vection. Blunting of both the release and action of vasopressin by atropine may explain its beneficial action in motion sickness.

Citing Articles

Relationship between plasma urea and copeptin in response to arginine stimulation in healthy adults, patients with vasopressin deficiency and primary polydipsia.

Atila C, Lustenberger S, Chifu I, Ferrante E, Erlic Z, Drummond J Pituitary. 2025; 28(1):18.

PMID: 39863827 PMC: 11762438. DOI: 10.1007/s11102-024-01489-7.


Risedronate prevents exercise-induced hypercalcemia but not nausea or vomit in humans: a double blind randomized controlled trial.

Senda M, Fujii N, Ito T, Isaka Y, Moriyama T, Hamano T Sci Rep. 2024; 14(1):22534.

PMID: 39341930 PMC: 11439016. DOI: 10.1038/s41598-024-73985-6.


Potential Biomarkers of Resilience to Microgravity Hazards in Astronauts.

Minoretti P, Fortuna G, Lavdas K, DAcquino D Cureus. 2024; 16(3):e57173.

PMID: 38681405 PMC: 11056033. DOI: 10.7759/cureus.57173.


Synergistic augmentation of rhythmic myogenic contractions of human stomach by arginine vasopressin and adrenaline: Implications for the induction of nausea.

Makwana R, Crawley E, Straface M, Palmer A, Gharibans A, Devalia K Br J Pharmacol. 2022; 179(24):5305-5322.

PMID: 36068676 PMC: 9826163. DOI: 10.1111/bph.15943.


Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.

Henze L, Foth S, Meller S, Twele F, Charalambous M, Kenward H J Vet Intern Med. 2022; 36(5):1726-1732.

PMID: 35906792 PMC: 9511069. DOI: 10.1111/jvim.16504.